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Abstract (N=177 words) 
Liver fibrosis is a polygenic disorder that supposed to share substantial genetic risk factors 
between the different etiologies of chronic liver diseases. MBOAT7 rs641738 is a cirrhosis risk 
gene that was recently identified by genome-wide association study in alcoholic cirrhosis. Here, 
we explore the role of rs641738 in two large cohorts of CHB (n=1101); of European (n=598) 
and Chinese ancestries (n=503). We also undertook gene expression analysis to detect the 
functional effects of the rs641738 SNP on MBOAT7 expression in liver biopsy samples from 
CHB from both ethnic backgrounds. We demonstrated that rs641738 impacts hepatic 
inflammation and fibrosis in the cohort of European (OR: 1.34, 95% CI: 1.02-2.04, p=0.03 and 
OR: 1.27, 95% CI: 1.07-2.83, p=0.04, respectively) but not in Chinese. It has no effect on 
steatosis or metabolic profile in both cohorts. We also found rs641738 was associated with 
MBOAT7 expression in liver biopsies from European but not Chinese. We conclude that 
rs641738 polymorphism in MBOAT7 is a novel risk variant for liver disease progression in 





 Hepatitis B virus (HBV) infection remains a worldwide public health challenge with an 
estimated two billion people infected and over one million deaths annually due to fulminant 
hepatitis B, liver cirrhosis, or hepatocellular carcinoma (HCC) (1). Liver disease associated with 
chronic hepatitis B (CHB) is induced by inflammatory processes initiated when the host immune 
response attempts to eliminate the hepatitis B virus. In addition, a complex interplay between 
host genetics, the immune response and viral factors  modulates the final outcome of hepatitis B 
infection (2).  
 While hepatitis B infection exists in all geographic contexts and continents, the disease is 
endemic with high prevalence in certain populations including in east Asia, sub-saharan Africa 
and around the Mediterranean basin (3). The reason for the variable prevalence rates is not 
known, but contributing factors include differences in host-virus interactions and socioeconomic 
or cultural practices. Accumulating evidence suggests that host genetics are important 
contributors to the risk of HBV persistence and progression (4). Hence a better understanding of 
host genomics in HBV infected patients is pivotal as it may allow the development of biomarkers 
for disease prognosis and treatment outcomes, the elucidation of mechanisms for disease 
pathogenesis and the identification of potential therapeutic targets (4). 
 Recently, a genome-wide association study (GWAS) identified a variant rs641738 in the 
Membrane Bound O-Acyltransferase Domain Containing 7 gene (MBOAT7) to be associated 
with alcoholic cirrhosis (5). Since the pathways leading to inflammation and fibrosis severity 
might be similar irrespective of the inciting injury, we explored the role of MBOAT7 rs641738 
to liver disease phenotype in a large European population cohort with CHB. To test if our 
findings were universally applicable or particular to populations of a unique ancestry, we 
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conducted further analysis to determine the role of this polymorphism in a Chinese population. 
We subsequently undertook gene expression analysis to detect functional effects of the rs641738 
polymorphism on MBOAT7 expression in liver biopsy samples from patients with CHB of both 
ethnic backgrounds, supplemented by analysis of publically available datasets for expression 





 The study comprised two independent consecutive cohorts with histologically 
characterized CHB from the International Liver Disease Genetics Consortium (ILDGC) database 
(n=1101).  The first included 598 European Caucasian patients and the second comprised a 
cohort of 503 Chinese patients. Details of the cohort and inclusion criteria have been reported 
(6,7). Briefly, all patients had detectable hepatitis B surface antigen (HBsAg), persistently or 
intermittently abnormal alanine aminotransferase (ALT) values, and serum HBV DNA >2,000 
IU/mL lasting for >6 months with at least one liver biopsy prior to any therapy. Patients were 
excluded if they had evidence of co-infection with either hepatitis C virus (HCV), hepatitis delta 
virus (HDV) or human immunodeficiency (HIV) virus, had evidence of other liver diseases by 
standard tests or current or previous hepatic decompensation.   
 Ethics approval was obtained from the Human Research Ethics Committees of the 
Sydney West Local Health District and the University of Sydney. All other sites had ethics 
approval from their respective ethics committees. Written informed consent for genetic testing 
was obtained from all participants.  
Clinical and laboratory assessment 
 The following data were collected at time of liver biopsy from all patients: gender, age, 
ethnicity, recruitment center, alcohol intake (gms/day), body mass index (BMI), HBV-DNA 
level, HBe-Ag status and routine laboratory tests. Alcohol consumption was assessed by 2 
separate interviews with the patient and close family members. BMI was calculated as weight 




 Genotyping for MBOAT7 rs641738 was undertaken using the TaqMan SNP genotyping 
allelic discrimination method (Applied Biosystems, Foster City, CA, USA). Genotyping for 
TM6SF2 rs58542926 and PNPLA3 rs738409 was contracted to the Australian Genome Research 
Facility (AGRF; QLD, Australia) and samples were genotyped using the Sequenom 
MassARRAY system and iPLEX Gold chemistry.  All genotyping was blinded to clinical 
variables.  
Liver Histopathology 
 Liver histopathology was scored by expert pathologists according to METAVIR (8). 
Fibrosis was staged from F0 (no fibrosis) to F4 (cirrhosis). Necroinflammation (A) was graded 
as A0 (absent), A1 (mild), A2 (moderate), or A3 (severe). Steatosis was quantified as follows: 
grade 0: absent or <5% of hepatocytes involved; grade 1: 5%-33%; grade 2: 34%-66%; and 
grade 3: >66% of hepatocytes affected. The inter-observer agreement between pathologists was 
studied previously and was good (κ = 77.5) for METAVIR staging using κ statistics (9).   
Statistical methods  
 Statistical methods are detailed in supplementary methods. All tests were two-tailed and 
p values <0.05 were considered significant. 
Population genetic analysis 
 
 Global distribution of the MBOAT7 rs641738 among 53 populations was derived from 
the Human Genome Diversity Project (HGDP) browser (http://hgdp.uchicago.edu/) (10). 
Gene expression analysis 
 To determine the functional effects of MBOAT7 rs641738, we undertook three analyses. 
In the first, we examined for the association of hepatic MBOAT7 expression according to 
8 
 
MBOAT7 rs641738 genotype in two well characterized and matched cohorts of CHB patients of 
European (n=21) and Chinese (n=21) ancestry. The details of RT-PCR are provided in the 
supplementary methods. Next we interrogated multiple publicly available databases containing 




MBOAT7 rs641738 minor allele frequency in the HBV cohort of European ancestry 
 The clinical, anthropometric and biochemical characteristics of patients in the HBV 
cohort of European ancestry are presented in supplementary table 1. The genotype distribution 
of MBOAT7 rs641738 was in Hardy-Weinberg equilibrium. The minor allele frequency (MAF) 
of MBOAT7 rs641738 was 0.436 (supplementary table 2), similar to that observed in a healthy 
Caucasian population from the 1000 genome project (http://browser.1000genomes.org). There 
was no significant difference in rs641738 allele frequency distribution according to patient 
country of origin (p=0.4 for trend).  
Association between MBOAT7 rs641738 and viral, clinical and metabolic characteristics in 
the HBV cohort of European ancestry 
 Apart from the fact that subjects with the rs641738 T allele had significantly higher GGT 
levels compared to subjects with CC genotype, no other significant associations were observed 
with any other clinical or viral characteristics. As regards the metabolic profile, data was only 
available in 98 subjects; in this sub-cohort, no significant associations were observed with the 
lipid or glycemic profile (Supplementary Table 3). 
MBOAT7 rs641738 and liver histology in the HBV cohort of European ancestry 
 We next assessed the impact of rs641738 on hepatic histological features including 
inflammation, fibrosis and steatosis. The distribution of rs641738 genotypes according to 
histological features are depicted in Figure 1.  In multivariate ordinal regression analysis 
adjusted for covariates including age, gender, T2DM, recruitment centre, PNPLA3 and TM6SF2 
genotypes, HBe-Ag status, MBOAT7 rs641738 was associated with the severity of 
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necroinflammation (β=0.085±0.043, 95% CI: 0.023-0.173, p=0.03) and fibrosis (β=0.079±0.031, 
95% CI:0.023-0.225, p=0.04). In further analysis subdividing the cohort into those with mild 
necroinflammation (A0–1) and severe necroinflammation (A2–A3), again the rs641738 T allele 
was independently associated with severe necroinflammation (OR: 1.34, 95% CI: 1.02-2.04, 
p=0.03) in multiple logistic regression analysis adjusting for the same variables (Table 1). 
Similarly for fibrosis, rs641738 T allele was associated with significant fibrosis (≥ F2) (OR: 
1.27, 95% CI: 1.07-2.83, p=0.04) (Table 1). Hepatic steatosis scoring was only available in 373 
(62%) subjects; in those, rs641738 T allele has no impact on steatosis grade (β=0.044±0.014, 
95% CI: 0.006-0.376, p=0.5) or moderate/severe steatosis (S2-S3) (OR: 1.06, 95% CI: 0.53-1.88, 
p=0.9). 
MBOAT7 rs641738 minor allele frequency in the HBV cohort of Chinese ancestry   
 To replicate our results, we tested whether rs641738 was associated with histological 
features in Chinese patients with CHB. In this cohort of 503 patients, the genotype distribution of 
MBOAT7 rs641738 was in Hardy-Weinberg equilibrium. The MAF was dramatically lower than 
in Europeans (MAF=0.24), an observation that was similar in a Chinese population from the 
1000 genome project (MAF=0.22-0.24). To examine for the detailed global allele frequency 
distributions of MBOAT7 rs641738, we next compared its allele frequencies in 53 world 
populations. Intriguingly, MBOAT7 rs641738 showed dramatic differences in derived allele 
frequency (T allele) with the highest frequencies in Europe and South Asia, followed by North 
and southern Africa and lowest in East Asia (Figure 2). 
 Apart from the fact that subjects with rs641738 T allele had significantly higher alkaline 
phosphatase levels, compared to subjects with CC genotype, no differences in clinical, 
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anthropometric, viral or biochemical parameters including circulating lipids and blood glucose 
were detected across MBOAT7 rs641738 genotypes (Supplementary Table 6). 
MBOAT7 rs641738 is not associated with liver injury in the HBV cohort of Chinese 
ancestry 
 We next assessed the impact of rs641738 on histological features including 
inflammation, fibrosis and steatosis in the HBV cohort of Chinese ancestry. In contrast to the 
observed association of rs641738 with liver injury in Europeans, this was not replicated in the 
Chinese cohort. The distribution of rs641738 genotypes according to histological features 
(inflammation, fibrosis and steatosis grade) are depicted in Figure 3.   
 MBOAT7 rs641738 was not associated with the severity of necroinflammation 
(β=0.059±0.049, 95% CI: 0.026-0.167, p=0.1), fibrosis (β=0.043±0.035, 95% CI: 0.016-0.219, 
p=0.4) or steatosis (β=0.035±0.012, 95% CI: 0.017-0.179, p=0.5) (Supplementary Table 7). In 
a further analysis, MBOAT7 rs641738 was not associated with severe necroinflammation (OR: 
1.16, 95% CI: 0.97-1.68, p=0.1), significant fibrosis (≥ F2) (OR: 1.09, 95% CI: 0.87-1.85, p=0.4) 
or moderate/severe steatosis (S2-S3) (OR: 1.05, 95% CI: 0.8-2.28, p=0.6) (Table 2). 
 To further explore for a potential explanation for the differential effects on liver histology 
between European and Chinese CHB cohorts, we repeated the analysis using different genetic 
models; the same results were obtained. The same results were also obtained when subjects with 
HBe-Ag negative or positive disease or high (i.e. equal or higher than median) or low HBV-
DNA levels were analyzed separately (data not shown).   
 We also performed a power analysis using the G*power program (13) based on Cohen’s 
method (14). The European and Chinese sample sizes revealed >98% and >95% power to detect a 
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significant association (α<0.05), respectively, given an effect size index of 0.2 (which 
corresponds to a weak to moderate gene effect), hence the possibility that this negative 
association was due to lack of power is less likely.  
 In total, in contrast to the effect rs641738 on liver injury in patients infected with CHB of 
European descent, it had no effect on those of Chinese descent. 
rs641738 genotype associates with MBOAT7 mRNA expression in liver biopsies from 
European but not in Chinese patients 
 To reconcile the above findings, we investigated the functional impact of rs641738 on 
hepatic MBOAT7 expression in liver biopsies from two well characterized sub-cohorts of 
Europeans and Chinese patients, correcting for difference in MAF between both groups (n=21 
per each group). Apart from the fact that Europeans had a higher BMI, the baseline 
characteristics of both groups were matched and are summarized in supplementary table 8; the 
sub-cohort were also matched with the overall cohort. In this analysis, rs641738 genotype was 
associated with hepatic MBOAT7 expression in liver biopsies from European but not Chinese 
subjects (Figure 4), further supporting our genetics observations.    
 Finally, we explored multiple publicly available eQTL databases. Consistent with our 
data, in a genome-wide eQTL mapping of human liver samples from Caucasian patients, 
rs641738 was associated with hepatic MBOAT7 expression (p= 3.65x10-12) (12), while in a set of 
Chinese liver tissue samples, at the 5% FDR level, no association with hepatic MBOAT7 




 To our knowledge, this is the first study to explore the role of polymorphisms at 
MBOAT7 rs641738 on the liver phenotype of patients with CHB. We demonstrate that rs641738 
impacts hepatic inflammation and fibrosis in Europeans with CHB. These observations were not 
replicated in a cohort of Chinese ancestry, a finding supported by publically available MBOAT 
expression eQTL datasets from liver, as well as our data on MBOAT7 expression in liver 
biopsies from Chinese and European patients with chronic hepatitis B.  
  In the European cohort, subjects carrying the MBOAT7 rs641738 T minor allele 
demonstrated an increased risk of hepatic inflammation and fibrosis. This effect was independent 
of other risk factors including age at time of biopsy, gender, HBe-Ag status, T2DM, recruitment 
centre, and other related risk variants, i.e. PNPLA3 rs738409 and TM6SF2 rs58542926 
genotype.  These findings in CHB for Europeans are consistent with what has recently been 
reported in alcoholic and non alcoholic fatty liver diseases and recently by us in Caucasians with 
hepatitis C (manuscript submitted) (5,15). In contrast, no similar effects according to MBOAT7 
rs641738 genotype were present in those of Chinese descent either with regard to liver 
histological phenotype or hepatic MBOAT expression. To our knowledge, no other studies have 
explored the role of MBOAT7 to liver injury in Chinese population for any liver disease. 
Collectively, these data, in the context of other published reports (5,15) suggest that rs641738 is a 
novel risk variant for hepatic inflammation (and consequently fibrosis), in Europeans across 
multiple liver diseases.  
 Notably, both European and Caucasian cohorts had a balanced distribution of fibrosis 
stage (~60% and 55% with ≥ F2 in the European and Chinese cohorts, respectively), age and 
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gender indicating that this is unlikely a cause for the discrepancy in results. This suggests that 
either the MBOAT7 variant examined herein might not be a risk gene for HBV-related liver 
injury in Chinese populations, or that genetic heterogeneity may be an additional explanation for 
the negative results. In the latter case, other risk variants rather than rs641738 in the MBOAT7 
gene could be a risk variant for liver injury in Chinese, however, it should be noted that no 
association between any variant and hepatic MBOAT7 expression in Chinese cohort from 
available eQTL dataset was reported (12). Further fine mapping studies in Chinese populations 
could help in resolving this issue. As the variation in genotypic relative risk across different 
populations may also be attributed to interactions with unmeasured factors that are unique to 
specific populations, another intriguing but untested possibility raised by the present findings is 
that MBOAT7 rs641738 might influence hepatic inflammation and fibrosis in Chinese 
populations, only according to specific liver disease etiologies. Further studies to investigate the 
role of MBOAT7 rs641738 in other liver disease etiologies are thus required.  
 Notably, there are ethnic differences in the allele frequency of the MBOAT7 rs641738 
polymorphism between European (MAF=~ 0.45) and East Asian populations (~0.24), in the 
healthy population from the 1000 genome project as well as in the present cohorts. Hence, to 
explore if sample size is likely to explain the negative associations observed by us in Chinese, 
we undertook power analysis. This confirmed that both cohorts had > 95% power to detect an 
effect size index of 0.2 (which corresponds to a weak to moderate gene effect). However, our 
cohorts were not powered to detect an effect size index of 0.1 (which corresponds to a weak gene 




 It is noteworthy that rs641738 controls hepatic expression of MBOAT7 in Europeans but 
not in Chinese, a result consistent with publically available eQTL data and with the previously 
reported variation in expression levels of many other genes between human populations (16,17). 
This variation among populations could be explained by the fact that the contribution of an allele 
in any given population depends upon its allele frequency (16), but more importantly by 
population-specific genotypic effects, as reported previously (17). On the other hand, further 
detailed evolutionary analyses would be required to understand the major forces shaping the 
genetic diversity of MBOAT7 between Europeans and Chinese. Such analyses of population 
genetic histories may aid in explaining the frequently observed inconsistency in genetic 
associations for complex diseases between different ethnic populations (18). 
 The detailed functional mechanisms of MBOAT7 action are still not completely known. 
MBOAT7 (Lysophospholipid acyltransferase) belongs to the remodeling pathway of 
phosphoinositides (Land's cycle) that attaches arachidonic acids (AA) to 
lysophosphatidylinositol (19) to reduce free AA levels. Free AA induces apoptosis (20), which is a 
potent trigger of hepatic inflammation and fibrosis (21) and amplifies the inflammatory response 
in macrophages and other immune cells (22). Thus, upregulation of MBOAT7 in response to a 
hepatic insult might be a compensatory or adaptive mechanism, similar to that observed in other 
contexts such as intrauterine growth restriction and shock (23).    
 In conclusion, we provide evidence that MBOAT7 rs641738 contributes to hepatic 
inflammation and fibrosis in European but not Chinese patients with chronic hepatitis B. The 
reasons for this differential effect are unknown, but warrants further evolutionary analyses of 
MBOAT7 variants in Chinese populations with CHB and also those with other liver diseases 
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